Cargando…
Targeting Selectins and Their Ligands in Cancer
Aberrant glycosylation is a hallmark of cancer cells with increased evidence pointing to a role in tumor progression. In particular, aberrant sialylation of glycoproteins and glycolipids has been linked to increased immune cell evasion, drug evasion, drug resistance, tumor invasiveness, and vascular...
Autores principales: | Natoni, Alessandro, Macauley, Matthew S., O’Dwyer, Michael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834419/ https://www.ncbi.nlm.nih.gov/pubmed/27148485 http://dx.doi.org/10.3389/fonc.2016.00093 |
Ejemplares similares
-
Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model
por: Natoni, Alessandro, et al.
Publicado: (2020) -
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271
por: Natoni, A, et al.
Publicado: (2017) -
Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment
por: Natoni, Alessandro, et al.
Publicado: (2019) -
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity
por: Natoni, Alessandro, et al.
Publicado: (2023) -
Three to Tango: MUC1 as a Ligand for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade
por: Geng, Yue, et al.
Publicado: (2012)